Nathan Rice
Stock Analyst at Piper Sandler
(3.00)
# 1,454
Out of 4,979 analysts
56
Total ratings
54.29%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBIN Merchants Bancorp | Maintains: Overweight | $42 → $41 | $31.91 | +28.49% | 8 | Jul 30, 2025 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $47 → $49 | $39.79 | +23.15% | 4 | Jul 28, 2025 | |
| BFC Bank First | Maintains: Neutral | $115 → $137 | $129.70 | +5.63% | 8 | Jul 21, 2025 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $28.87 | +17.77% | 8 | Oct 29, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $71.75 | +3.14% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $135.42 | -37.97% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $135.93 | +44.93% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $18.76 | -52.03% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $655.60 | -33.65% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $302.01 | -22.85% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $31.06 | +167.22% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $18.25 | -17.81% | 1 | Dec 19, 2019 |
Merchants Bancorp
Jul 30, 2025
Maintains: Overweight
Price Target: $42 → $41
Current: $31.91
Upside: +28.49%
First Mid Bancshares
Jul 28, 2025
Maintains: Overweight
Price Target: $47 → $49
Current: $39.79
Upside: +23.15%
Bank First
Jul 21, 2025
Maintains: Neutral
Price Target: $115 → $137
Current: $129.70
Upside: +5.63%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $28.87
Upside: +17.77%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $71.75
Upside: +3.14%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $135.42
Upside: -37.97%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $135.93
Upside: +44.93%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $18.76
Upside: -52.03%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $655.60
Upside: -33.65%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $302.01
Upside: -22.85%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $31.06
Upside: +167.22%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $18.25
Upside: -17.81%